Lund, Sweden, January 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Peter Ellmark as Chief Scientific Officer (CSO). Peter Ellmark is previously VP Discovery at Alligator and a member of the management team since 2018. As CSO, Dr. Ellmark takes on the scientific leadership for the company, to further consolidate Alligator's strong position in tumor-directed immunotherapy. Peter Ellmark will be part of the Alligator's executive management team and report to CEO Per Norlén.
"Peter's scientific excellence will provide value for our entire business, which will be critical as we move our key projects forward and intensify our business development activities," says Per Norlén, CEO of Alligator Bioscience. "The appointment of a CSO, together with the previously announced recruitment of Dr Christina Reimer as CMO, is part of the company's ambitious pipeline strategy."
For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CET on January 15, 2021.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc. In addition, the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-Prime. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit www.alligatorbioscience.com.